# Black Diamond Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2020

- Company: [Black Diamond Therapeutics, Inc.](/companies/bdtx.md) (CIK 1701541)
- Form: 10-Q
- Filed: 2020-05-12
- Accepted by EDGAR: May 12, 2020, 07:34 ET
- Period: 2020-03-31
- Accession: 0001701541-20-000018
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1701541/000170154120000018/bdtx-20200331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1701541/000170154120000018/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2020-01-01 to 2020-03-31 | $7.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-01-01 to 2020-03-31 | −$12.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2020-01-01 to 2020-03-31 | −$12.1m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months, 2020-01-01 to 2020-03-31 | −$11.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2020-01-01 to 2020-03-31 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-03-31 | $357.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-03-31 | $362.1m | us-gaap:AssetsCurrent |
| Total assets | at 2020-03-31 | $362.8m | us-gaap:Assets |
| Current liabilities | at 2020-03-31 | $7.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-03-31 | $7.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-03-31 | $355.3m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1701541/000170154120000018/bdtx-20200331.htm

Filed May 12, 2020.
Source: SEC EDGAR, the filing index for accession 0001701541-20-000018. Last ingested by Listed: Nov 10, 2026, 16:37 ET. No prices; not investment advice.
